PE20081379A1 - Composiciones farmaceuticas que comprende nilotinib - Google Patents
Composiciones farmaceuticas que comprende nilotinibInfo
- Publication number
- PE20081379A1 PE20081379A1 PE2007001294A PE2007001294A PE20081379A1 PE 20081379 A1 PE20081379 A1 PE 20081379A1 PE 2007001294 A PE2007001294 A PE 2007001294A PE 2007001294 A PE2007001294 A PE 2007001294A PE 20081379 A1 PE20081379 A1 PE 20081379A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- nilotinib
- tensioactive
- benzamide
- amino
- Prior art date
Links
- 239000005536 L01XE08 - Nilotinib Substances 0.000 title abstract 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 title abstract 2
- 229960001346 nilotinib Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- -1 3-PYRIDYL Chemical class 0.000 abstract 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000025113 myeloid leukemia Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 238000005550 wet granulation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN COMPUESTO INHIBIDOR DE LA CINASA DE PROTEINA TIROSINA (TK) DERIVADO DE PIRIMIDIL-AMINO-BENZAMIDA DE FORMULA (I), SIENDO PREFERIDO 4-METIL-3-[[4-(3-PIRIDINIL)-2-PIRIMIDINIL]-AMINO]-N-[5-(4-METIL-1H-IMIDAZOL-1-IL)-3-(TRIFLUORO-METIL)-FENIL]-BENZAMIDA O NILOTINIB COMO SAL MONOHIDRATO DE CLORHIDRATO. ESTA COMPOSICION SE PRESENTA BAJO LA FORMA DE DOSIFICACION SOLIDA, EN ESPECIAL COMO CAPSULA, LAS CUALES SE RELLENAN CON GRANULOS QUE CONTIENEN DICHO COMPUESTO, MEZCLADO CON UNA FASE EXTERNA QUE COMRENDE AL MENOS UN EXCIPIENTE TAL COMO UN TENSIOACTIVO SIENDO PREFERIDO UN POLOXAMERO 188, AMASADOS EN HUMEDO. TAMBIEN SE REFIERE UN PROCEDIMIENTO DE PREPARACION DE GRANULACION HUMEDA; SIENDO UTILES EN EL TRATAMIENTO DE LEUCEMIA MIELOIDE Y TUMORES GASTROINTESTINALES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06121371A EP1923053A1 (en) | 2006-09-27 | 2006-09-27 | Pharmaceutical compositions comprising nilotinib or its salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081379A1 true PE20081379A1 (es) | 2008-11-27 |
Family
ID=37684496
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000043A PE20120626A1 (es) | 2006-09-27 | 2007-09-25 | Composiciones farmaceuticas que comprende nilotinib |
| PE2007001294A PE20081379A1 (es) | 2006-09-27 | 2007-09-25 | Composiciones farmaceuticas que comprende nilotinib |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000043A PE20120626A1 (es) | 2006-09-27 | 2007-09-25 | Composiciones farmaceuticas que comprende nilotinib |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US8293756B2 (es) |
| EP (4) | EP1923053A1 (es) |
| JP (2) | JP5567340B2 (es) |
| KR (2) | KR20090076931A (es) |
| CN (2) | CN104306350A (es) |
| AR (1) | AR062980A1 (es) |
| AU (1) | AU2007301977B2 (es) |
| BR (1) | BRPI0719438B1 (es) |
| CA (1) | CA2662571C (es) |
| CL (1) | CL2007002766A1 (es) |
| CO (1) | CO6160288A2 (es) |
| CY (2) | CY1117021T1 (es) |
| DK (2) | DK3984528T3 (es) |
| ES (3) | ES2951547T3 (es) |
| FI (2) | FI2068839T4 (es) |
| HK (1) | HK1133193A1 (es) |
| HR (2) | HRP20151383T4 (es) |
| HU (2) | HUE028204T2 (es) |
| IL (1) | IL197496A (es) |
| JO (1) | JO3757B1 (es) |
| LT (1) | LT3984528T (es) |
| MA (1) | MA30807B1 (es) |
| MX (1) | MX2009003184A (es) |
| MY (1) | MY148237A (es) |
| NO (2) | NO346639B1 (es) |
| NZ (1) | NZ575317A (es) |
| PE (2) | PE20120626A1 (es) |
| PL (2) | PL3984528T3 (es) |
| PT (2) | PT3984528T (es) |
| RU (1) | RU2469707C2 (es) |
| SI (2) | SI2068839T2 (es) |
| TN (1) | TN2009000093A1 (es) |
| TW (3) | TWI540128B (es) |
| WO (1) | WO2008037716A2 (es) |
| ZA (1) | ZA200901511B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1923053A1 (en) | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
| CA2775400A1 (en) | 2009-09-28 | 2011-03-31 | Medizinische Universitat Wien | New use of pdgfrbeta inhibitors |
| WO2011050120A1 (en) * | 2009-10-23 | 2011-04-28 | Novartis Ag | Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity |
| JO3634B1 (ar) | 2009-11-17 | 2020-08-27 | Novartis Ag | طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r |
| IN2011CH01887A (es) * | 2011-06-02 | 2012-12-14 | ||
| AR086913A1 (es) * | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas |
| CN102321073A (zh) * | 2011-08-12 | 2012-01-18 | 西安交通大学 | 一种尼罗替尼的制备方法 |
| WO2013063003A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
| JP2014532647A (ja) | 2011-10-28 | 2014-12-08 | ノバルティス アーゲー | 消化管間質腫瘍を治療する方法 |
| WO2013074432A1 (en) * | 2011-11-14 | 2013-05-23 | Novartis Ag | Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation |
| US9301957B2 (en) | 2011-11-14 | 2016-04-05 | Novartis Ag | Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation |
| CN104427986A (zh) | 2012-07-11 | 2015-03-18 | 诺华股份有限公司 | 治疗胃肠道基质瘤的方法 |
| EP2988729A1 (en) | 2013-04-25 | 2016-03-02 | Sun Pharmaceutical Industries Limited | Pharmaceutical gastro-retentive solid oral dosage form of nilotinib |
| US9636340B2 (en) | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
| SI3189045T1 (sl) | 2014-08-11 | 2022-05-31 | Sun Pharmaceutical Industries Limited | Nove soli nilotiniba in njih polimorfi |
| WO2016033304A1 (en) * | 2014-08-28 | 2016-03-03 | Codexis, Inc. | Imidazoyl anilide derivatives and methods of use |
| CN114209702A (zh) * | 2016-03-17 | 2022-03-22 | 太阳制药工业公司 | 尼洛替尼的药物组合物 |
| CN107582531B (zh) * | 2016-07-06 | 2020-12-29 | 四川科伦药物研究院有限公司 | 一种利伐沙班固体制剂及其制备方法 |
| CN107320460B (zh) * | 2017-08-04 | 2020-11-03 | 北京化工大学 | 一种尼罗替尼口服纳米制剂及其制备方法 |
| CN107441094B (zh) * | 2017-08-08 | 2020-05-22 | 南方医科大学 | 尼罗替尼作为治疗登革病毒感染的药物及其制药用途 |
| CZ2017821A3 (cs) | 2017-12-20 | 2019-07-03 | Zentiva, K.S. | Léková forma obsahující krystalický nilotinib |
| CN113292537B (zh) | 2018-06-15 | 2024-04-05 | 汉达癌症医药责任有限公司 | 激酶抑制剂的盐类及其组合物 |
| WO2021155254A1 (en) | 2020-01-31 | 2021-08-05 | Nanocopoeia, Llc | Amorphous nilotinib microparticles and uses thereof |
| IL297776A (en) | 2020-04-30 | 2022-12-01 | Nanocopoeia Llc | Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib |
| EP4355306A1 (en) | 2021-06-19 | 2024-04-24 | Helm AG | Granulate composition comprising nilotinib |
| WO2023285981A1 (en) * | 2021-07-15 | 2023-01-19 | Torrent Pharmaceuticals Limited | Stable pharmaceutical liquid composition of nilotinib |
| EP4122452A1 (en) | 2021-07-23 | 2023-01-25 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising nilotinib and method of manufacturing the same |
| EP4260848A1 (en) | 2022-04-11 | 2023-10-18 | Lotus Pharmaceutical Co., Ltd. | Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4072535A (en) * | 1970-12-28 | 1978-02-07 | A. E. Staley Manufacturing Company | Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules |
| FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
| JP3125221B2 (ja) * | 1990-09-01 | 2001-01-15 | 大正製薬株式会社 | ソファルコン含有固形製剤 |
| HU217629B (hu) * | 1991-12-12 | 2000-03-28 | Novartis Ag. | Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására |
| TW442301B (en) * | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
| ES2339425T3 (es) | 1996-07-24 | 2010-05-20 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-il)-ftalimidas y -1-oxoisoindolinas sustituidas y procedimiento para reducir los niveles de tnf-alfa. |
| TW426516B (en) * | 1996-12-06 | 2001-03-21 | Fujisawa Pharmaceutical Co | An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds |
| FR2783421B1 (fr) * | 1998-09-17 | 2000-11-24 | Cll Pharma | Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications |
| FR2795961B1 (fr) * | 1999-07-09 | 2004-05-28 | Ethypharm Lab Prod Ethiques | Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation |
| EA004872B1 (ru) | 1999-08-03 | 2004-08-26 | ЛИЛЛИ АЙКОС эЛ-эЛ-Си | β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ |
| BR0008059A (pt) * | 1999-12-08 | 2002-03-26 | Pharmacia Corp | Composições de valdecoxib |
| JP2003519698A (ja) | 2000-01-07 | 2003-06-24 | トランスフォーム ファーマスーティカルズ，インコーポレイテッド | 多様な固体形態のハイスループットでの形成、同定および分析 |
| BR0312445A (pt) * | 2002-06-07 | 2005-05-10 | Ranbaxy Lab Ltd | Sistemas multiunitários para disponibilização de fármaco de liberação modificada |
| GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| US7910030B2 (en) * | 2002-11-26 | 2011-03-22 | Universiteit Gent | Process and apparatus for continuous wet granulation of powder material |
| KR20040076203A (ko) * | 2003-02-24 | 2004-08-31 | 주식회사 엘지생명과학 | 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법 |
| EP1653927B1 (en) * | 2003-08-04 | 2012-01-11 | Bend Research, Inc. | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
| TR200301553A1 (tr) | 2003-09-18 | 2005-10-21 | Nobel �La� Sanay�� Ve T�Caret A.�. | İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar |
| GB0325031D0 (en) | 2003-10-27 | 2003-12-03 | Novartis Ag | Organic compounds |
| WO2005065653A1 (en) * | 2003-12-19 | 2005-07-21 | E.I. Du Pont De Nemours And Company | Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution |
| WO2006013444A1 (en) | 2004-07-28 | 2006-02-09 | Ranbaxy Laboratories Limited | Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation |
| KR20070057901A (ko) * | 2004-10-01 | 2007-06-07 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미립자 함유 조성물 및 그의 제조 방법 |
| WO2006066932A1 (en) * | 2004-12-24 | 2006-06-29 | Lek Pharmaceuticals D.D. | Stable pharmaceutical composition comprising an active substance in the form of solid solution |
| WO2006079539A2 (en) * | 2005-01-28 | 2006-08-03 | Novartis Ag | Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity |
| AU2006218020A1 (en) * | 2005-02-25 | 2006-08-31 | Novartis Ag | Pharmaceutical combination of Bcr-Abl and RAF inhibitors |
| GT200600315A (es) | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
| GT200600316A (es) | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
| BRPI0714963A2 (pt) * | 2006-08-16 | 2013-07-30 | Novartis Ag | processo de fabricaÇço de dispersÕes sàlidas de compostos terapÊuticos altamente cristalinos |
| EP1923053A1 (en) * | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
-
2006
- 2006-09-27 EP EP06121371A patent/EP1923053A1/en not_active Ceased
-
2007
- 2007-09-23 JO JOP/2007/0402A patent/JO3757B1/ar active
- 2007-09-25 NO NO20091501A patent/NO346639B1/no unknown
- 2007-09-25 BR BRPI0719438-2A patent/BRPI0719438B1/pt active IP Right Grant
- 2007-09-25 PE PE2012000043A patent/PE20120626A1/es not_active Application Discontinuation
- 2007-09-25 SI SI200731724T patent/SI2068839T2/sl unknown
- 2007-09-25 CA CA2662571A patent/CA2662571C/en active Active
- 2007-09-25 HR HRP20151383TT patent/HRP20151383T4/hr unknown
- 2007-09-25 FI FIEP07820560.6T patent/FI2068839T4/fi active
- 2007-09-25 AU AU2007301977A patent/AU2007301977B2/en active Active
- 2007-09-25 ES ES21194622T patent/ES2951547T3/es active Active
- 2007-09-25 PL PL21194622.3T patent/PL3984528T3/pl unknown
- 2007-09-25 JP JP2009529688A patent/JP5567340B2/ja active Active
- 2007-09-25 DK DK21194622.3T patent/DK3984528T3/da active
- 2007-09-25 WO PCT/EP2007/060165 patent/WO2008037716A2/en active Application Filing
- 2007-09-25 KR KR1020097008418A patent/KR20090076931A/ko not_active Application Discontinuation
- 2007-09-25 AR ARP070104231A patent/AR062980A1/es not_active Application Discontinuation
- 2007-09-25 US US12/442,544 patent/US8293756B2/en active Active
- 2007-09-25 ES ES15184282T patent/ES2957912T3/es active Active
- 2007-09-25 CN CN201410535689.8A patent/CN104306350A/zh active Pending
- 2007-09-25 KR KR1020147027439A patent/KR101598747B1/ko active IP Right Grant
- 2007-09-25 NZ NZ575317A patent/NZ575317A/en unknown
- 2007-09-25 HU HUE07820560A patent/HUE028204T2/en unknown
- 2007-09-25 LT LTEP21194622.3T patent/LT3984528T/lt unknown
- 2007-09-25 SI SI200732199T patent/SI3984528T1/sl unknown
- 2007-09-25 PE PE2007001294A patent/PE20081379A1/es active IP Right Grant
- 2007-09-25 MX MX2009003184A patent/MX2009003184A/es active IP Right Grant
- 2007-09-25 EP EP07820560.6A patent/EP2068839B2/en active Active
- 2007-09-25 EP EP15184282.0A patent/EP3009128B1/en active Active
- 2007-09-25 HR HRP20230753TT patent/HRP20230753T3/hr unknown
- 2007-09-25 EP EP21194622.3A patent/EP3984528B1/en active Active
- 2007-09-25 PT PT211946223T patent/PT3984528T/pt unknown
- 2007-09-25 PT PT78205606T patent/PT2068839E/pt unknown
- 2007-09-25 NO NO20220946A patent/NO347404B1/no unknown
- 2007-09-25 DK DK07820560.6T patent/DK2068839T3/da active
- 2007-09-25 FI FIEP21194622.3T patent/FI3984528T3/fi active
- 2007-09-25 ES ES07820560T patent/ES2556625T5/es active Active
- 2007-09-25 PL PL07820560.6T patent/PL2068839T5/pl unknown
- 2007-09-25 RU RU2009115782/15A patent/RU2469707C2/ru active
- 2007-09-25 MY MYPI20091044A patent/MY148237A/en unknown
- 2007-09-25 HU HUE21194622A patent/HUE063083T2/hu unknown
- 2007-09-25 CN CNA2007800353567A patent/CN101516344A/zh active Pending
- 2007-09-26 TW TW102144088A patent/TWI540128B/zh active
- 2007-09-26 TW TW096135768A patent/TWI428333B/zh active
- 2007-09-26 TW TW103101056A patent/TW201418245A/zh unknown
- 2007-09-26 CL CL200702766A patent/CL2007002766A1/es unknown
-
2009
- 2009-03-03 ZA ZA2009/01511A patent/ZA200901511B/en unknown
- 2009-03-09 IL IL197496A patent/IL197496A/en active IP Right Grant
- 2009-03-19 TN TN2009000093A patent/TN2009000093A1/fr unknown
- 2009-04-22 MA MA31809A patent/MA30807B1/fr unknown
- 2009-04-24 CO CO09041795A patent/CO6160288A2/es unknown
- 2009-12-04 HK HK09111400.2A patent/HK1133193A1/xx active IP Right Maintenance
-
2012
- 2012-09-21 US US13/624,354 patent/US8501760B2/en active Active
-
2013
- 2013-11-07 JP JP2013231327A patent/JP2014065715A/ja active Pending
-
2015
- 2015-12-16 CY CY20151101150T patent/CY1117021T1/el unknown
-
2023
- 2023-07-27 CY CY20231100367T patent/CY1126116T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081379A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
| US10350206B2 (en) | Benzyl substituted indazoles as BUB1 inhibitors | |
| CN104302638B (zh) | 用于抑制abl1、abl2和bcr-abl1的活性的苯甲酰胺衍生物 | |
| US9809610B2 (en) | Compounds and compositions as kinase inhibitors | |
| ES2481408T3 (es) | Derivados sustituidos de indolilalquilaminas como inhibidores de histona-desacetilasas | |
| WO2020081880A1 (en) | Compositions targeting senescent cells and the uses thereof | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| US20170305882A1 (en) | Benzyl substituted indazoles as bub1 kinase inhibitors | |
| MX2009008953A (es) | Compuestos como inhibidores de angiogenesis. | |
| MX2009009843A (es) | Compuestos espiro sustituidos como inhibidores de la angiogenesis. | |
| PE20141855A1 (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| KR20150008406A (ko) | Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체 | |
| PE20061436A1 (es) | Derivados de amida sustituida como inhibidores de proteina quinasa | |
| ES2638179T3 (es) | Compuestos de pirrolopirimidina sustituidos, composiciones de los mismos, y métodos de tratamiento con los mismos | |
| WO2016042081A1 (en) | Benzyl substituted indazoles as bub1 kinase inhibitors | |
| MY148878A (en) | Stabilized amorphous forms of imatinib mesylate | |
| RU2017118165A (ru) | Ингибиторы энхансера гомолога 2 zestes | |
| EA201891315A1 (ru) | Твердые дисперсии, содержащие стимулятор sgc | |
| EA201990902A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| EA201891578A1 (ru) | Композиции 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил-2,2-дифторацетамида | |
| BR112020027064A2 (pt) | derivados de quinazolina do tipo éter biarílico | |
| HRP20150530T1 (hr) | Spojevi korisni za inhibiranje chk1 | |
| AR110995A1 (es) | Combinación de inhibidores de quinasa atr con sal de radio-223 | |
| HRP20100265T1 (hr) | Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti | |
| NZ590177A (en) | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |